Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Brii Biosciences Limited (7SS) Stock Price & Analysis

7SS Stock Chart & Stats

€0.10-€0.00(-4.81%)
At close: 5:30 PM GMT+1
EUR 0.09EUR 0.14 Aug10 Sep17 Sep2 Oct12 Oct27 Oct
Day’s Range
EUR 0.10 - EUR 0.10
52-Week Range
EUR 0.09 - EUR 0.22
Previous Close
EUR 0.10
Volume
0
Average Volume (3M)
54
Market Cap
EUR 80.60M
Enterprise Value
-EUR 1.40B
Total Cash (Recent Filing)
EUR 1.77B
Total Debt (Recent Filing)
EUR 6.18M
Price to Earnings (P/E)
―
Beta
1.56
Next Earnings
Mar 19, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage And Positive Equity

A lightly leveraged balance sheet reduces financial risk and preserves flexibility to fund operations, invest in development, or withstand setbacks. Positive equity also provides a capital cushion, although the company’s history shows that losses have previously pressured its financial position.

Reduced Loss And Cash Burn In 2025

The improvement in annual loss and cash outflow indicates some progress in controlling operating demands, even though the business remains unprofitable. If sustained, better cost discipline could extend liquidity and create a stronger foundation for future commercialization and development investment.

Partnered Asset-based Business Model

Using licensed and partnered assets can broaden the company’s product opportunity without requiring it to originate every therapy internally. External partners may also share development costs and support commercialization, creating potential access to milestone and royalty income over time.

Bears Say

Persistent Unprofitability

Continued losses and deeply negative margins show that the current business model has not yet reached sustainable profitability. This weakens internal funding capacity, increases dependence on liquidity or external capital, and makes future earnings power less predictable until operating economics improve.

Ongoing Cash Burn

Persistent negative operating and free cash flow means the company is not currently funding its activities from internally generated cash. Continued development and commercialization therefore depend on existing liquidity or external funding, which can constrain strategic flexibility and raise financing pressure.

Sharp Revenue Contraction

A sharp revenue decline undermines evidence of durable commercial scale and can reduce operating leverage across the business. Combined with ongoing losses, volatile sales make it harder to support development spending, demonstrate predictable demand, and move toward sustainable profitability.

Brii Biosciences Limited News

7SS FAQ

What was Brii Biosciences Limited’s price range in the past 12 months?
Brii Biosciences Limited lowest stock price was €0.09 and its highest was €0.22 in the past 12 months.
What is Brii Biosciences Limited’s market cap?
Brii Biosciences Limited’s market cap is €80.60M.
When is Brii Biosciences Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Brii Biosciences Limited’s earnings last quarter?
Brii Biosciences Limited released its earnings results on Aug 20, 2026. The company reported -€0.018 earnings per share for the quarter, missing the consensus estimate of -€0.014 by -€0.004.
Is Brii Biosciences Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Brii Biosciences Limited pay dividends?
Brii Biosciences Limited does not currently pay dividends.
What is Brii Biosciences Limited’s EPS estimate?
Brii Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Brii Biosciences Limited have?
Brii Biosciences Limited has 735,837,770 shares outstanding.
What happened to Brii Biosciences Limited’s price movement after its last earnings report?
Brii Biosciences Limited reported an EPS of -€0.018 in its last earnings report, missing expectations of -€0.014. Following the earnings report the stock price went up 5.155%.
Which hedge fund is a major shareholder of Brii Biosciences Limited?
Currently, no hedge funds are holding shares in DE:7SS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology